Vaccination in patients with immunosuppression

Arvas, Ahmet

doi:10.5152/tpa.2014.2206

Cited by 52 publications

(38 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other associations with immunodeficiency include age-dependent humoral and immune cell alterations; immunosenescence; malnutrition (19); protein-energy-micronutrient deficit and telomere shortening (20). In addition, past or current treatments affect the scalable ineffectiveness of vaccines in both older adults (21) and children (22), especially in immunocompromised (23).…”

Section: Vaccines: An Overviewmentioning

confidence: 99%

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

et al. 2020

View full text Add to dashboard Cite

In the current context of the pandemic triggered by SARS-cOV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS-cOV-2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a cOVId-19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.

show abstract

Section: Vaccines: An Overviewmentioning

confidence: 99%

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In contrast to RZV, ZVL is contraindicated in persons with immunodeficiency or immunosuppression due to disease or immunosuppressive therapy as live-virus vaccines can cause severe or fatal reactions in immunosuppressed persons due to uncontrolled replication of the vaccine virus. 18,[20][21][22][23] A candidate inactivated zoster vaccine (ZV IN ) evaluated in immunocompromised adults and adult autologous hematopoietic stem cell transplant (HSCT) recipients has been shown to be generally safe and immunogenic when administered in a 4-dose schedule over 4 months. [24][25][26] In the autologous HSCT recipients, the candidate ZV IN vaccine was 64% efficacious in preventing confirmed cases of HZ.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Vink

Mingorance

Alonso

et al. 2019

Cancer

View full text Add to dashboard Cite

; on behalf of the Zoster-028 Study Group BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) has demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age and 68% efficacy in autologous hematopoietic stem cell transplant recipients ≥18 years of age. We report the immunogenicity and safety of RZV administered to patients with solid tumors (STs) before or at the start of a chemotherapy cycle. METHOD: In this phase 2/3 observer-blind, multicenter study (NCT01798056), patients with STs who were ≥18 years of age were randomized (1:1) to receive 2 doses of RZV or placebo 1-2 months apart and stratified (4:1) according to the timing of the first dose with respect to the start of a chemotherapy cycle (first vaccination 8-30 days before the start or at the start [±1 day] of a chemotherapy cycle). Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4 + T cell frequencies, and vaccine response rates (VRRs) were assessed 1 month after dose 1 and 1 and 12 months after dose 2. Reactogenicity and safety were assessed in the total vaccinated cohort through 12 months after dose 2. RESULTS: There were 232 participants in the total vaccinated cohort, 185 participants in the according-to-protocol cohort for humoral immunogenicity, and 58 participants in the according-to-protocol cohort for cell-mediated immunogenicity. Postvaccination anti-gE antibody concentrations, gE-specific CD4 + T cell frequencies and VRRs were higher in RZV recipients than in placebo recipients. Solicited adverse events (AEs) were more frequent among RZV recipients than placebo recipients. Incidence of unsolicited AEs, serious AEs, fatalities, and potential immune-mediated diseases were similar between RZV and placebo recipients. CONCLUSION: RZV was immunogenic in patients with STs receiving immunosuppressive chemotherapies. Humoral and cell-mediated immune responses persisted 1 year after vaccination. No safety concerns were identified.

show abstract

“…Die Rotavirus-Impfung kann nach entsprechender Aufklärung und individueller Risiko-Nutzenabwägung (z. B. erhöhte Transmissionsgefahr durch junge, ungeimpfte Geschwisterkinder, die in einer Kindertageseinrichtung betreut werden) Säuglingen in Haushalten mit immunsupprimierten Personen während des in der Fachinformation angegebenen Zeitfensters verabreicht werden [89,90].…”

Section: Impfen Von Kontaktpersonenunclassified